CONMED Q2 FY26 earnings call CNMD

CONMED successfully completed the divestiture of its gastroenterology (GI) product offerings, with the final sale closing in Q2 FY26. This strategic exit, which included a manufacturing services agreement for 12 months to ensure customer continuity, sharpens the company's focus on its core growth markets: minimally invasive, robotic, and laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair. This move is expected to position CONMED for long-term value creation by concentrating resources on its strongest opportunities.

Over the past year, CONMED has made significant progress in strengthening its supply chain. The company has improved service levels, reduced back orders to their lowest levels in years, and built greater stability across its network. Management noted a transition from a state of recovery to one focused on operational enhancements, with continued investment planned to build an efficient and resilient supply chain to support future growth, margin expansion, and reliable customer service.

In Q2 FY26, CONMED successfully refinanced a portion of its debt, securing a new $450 million senior secured term loan facility that matures in 2030. The proceeds, combined with borrowings from its revolving credit facility, were used to repurchase $645.2 million of convertible notes for $637.2 million that were set to mature in June 2027. This action meaningfully reduces exposure to upcoming debt obligations and simplifies the company's capital structure.

CONMED strengthened its leadership team and Board of Directors during the quarter. Celine Martin and Jeff Mirviss, both with extensive global medtech leadership experience, were appointed to the Board. John Gallagher was appointed as Chief Financial Officer, effective July 15, bringing nearly three decades of financial leadership and healthcare expertise. These appointments are expected to contribute to strong execution and long-term shareholder value creation.

The AirSeal Robotic solution received an expanded indication for use with Intuitive's 8-millimeter Hex cannulas, in addition to its existing indication for 8-millimeter round cannulas. This makes AirSeal compatible across Intuitive's multiport portfolio (X, Xi, and DV5). This milestone, achieved through extensive collaboration and technical testing with Intuitive, provides increased clarity in the market and supports continued growth for AirSeal in robotic-assisted surgery.

Buffalo Filter, CONMED's smoke evacuation platform, is benefiting from expanding legislation. Michigan and Maryland recently enacted laws requiring surgical smoke evacuation systems, bringing the total to 22 U.S. states covering approximately 57% of the population. With over 10 additional states having pending legislation, these tailwinds are expected to drive solid long-term growth for the direct smoke evacuation portfolio, which already delivered high single-digit to low double-digit growth in Q2.

BioBrace, a reinforced bioinductive implant, continues to drive Orthopedic Surgery sales, particularly in rotator cuff repairs. The launch of BioBrace RC, designed to streamline its use, has been well-received, enabling surgeons to augment repairs more consistently. Clinical data showing a 94% healing rate in high-risk patients, coupled with updated AAOS guidelines recommending augmentation, supports strong surgeon adoption and positions BioBrace as an important long-term growth driver.